Editorial Standards: How HairLongevity Reviews Evidence

Trust should be supported by a process readers can inspect. These standards describe how HairLongevity turns a question into a sourced page, how review requirements are assigned, and what happens when evidence or regulatory information changes.

1. Start with a defined reader question

Every page begins with a primary intent and a bounded set of secondary questions. The draft should answer those questions directly rather than collecting keywords around a broad topic. Important terms are defined, the intended audience is named, and the page distinguishes general education from personal medical advice.

2. Search for the right type of evidence

HairLongevity prioritizes systematic reviews, evidence-based guidelines, randomized trials, well-designed observational studies, and official regulatory documents. Source choice depends on the question. A drug label is authoritative for approved indications and warnings, while a systematic review is more useful for judging the overall consistency and size of treatment evidence.

Searches should favor original and authoritative sources over summaries. A secondary source may help identify a paper, but a claim should link to the original study, guideline, medical society, or regulator whenever practical. Each cited source record includes a plain-language summary and at least one important limitation.

3. Match the claim to the evidence

A source is not enough merely because it mentions the topic. Editors check:

• who was studied;
• what intervention or exposure was measured;
• what the comparison group received;
• which outcome was reported;
• how long participants were followed;
• whether the result was clinically meaningful as well as statistically significant;
• whether limitations make the claim less certain or less generalizable.

Laboratory findings can explain a plausible mechanism, but they do not establish a consumer outcome. An association cannot be rewritten as causation. A short trial cannot establish long-term safety or durability.

4. Grade evidence and regulation on separate axes

Our evidence framework treats evidence strength and regulatory status as different questions. FDA approval, FDA clearance, prescription status, over-the-counter status, professional performance, and supplement classification each describe a regulatory pathway or access category. They do not automatically establish comparative effectiveness.

When evidence is weak or conflicting, the article should say so in language proportional to the uncertainty. It should explain whether the problem is small samples, short follow-up, inconsistent methods, indirect outcomes, bias, or a lack of independent replication. Uncertainty is not filled with a stronger marketing conclusion.

5. Write for understanding and retrieval

Pages open with a direct answer, use descriptive headings, and place essential context near the claim. FAQ answers are written as complete, stand-alone responses and also appear in the visible article. Internal links connect readers to the biological foundation, assessment limits, relevant options, and source methods without sending them to pages that do not exist.

Search optimization never justifies inaccurate claims, invented expertise, filler, or mass-produced pages that add no distinct value.

6. Apply review according to risk

No. Pages that substantially discuss diagnosis, drugs, procedures, adverse effects, or other clinically sensitive claims require medical review. A completed review is shown only when a verified reviewer name, role, and date are present. An empty field or generic badge does not count. Until required sign-off is recorded, the page must remain a draft and must not be described as medically reviewed.

Reviewer identities and credentials must be verified before publication. The reviewer page lists reviewer information only after the corresponding work is complete. Legal review is separately required for comparative, product-specific, prescription, and procedure content where flagged.

7. Disclose commercial relationships

FOLIKL owns and publishes HairLongevity.com. That relationship is identified in the site header and footer and explained on the publisher page. Direct FOLIKL product modules are labeled From FOLIKL. Other sponsored, affiliate, or product-specific relationships, if introduced, should be identified clearly near the relevant content.

8. Update and correct the record

Yes. Articles may change when stronger evidence appears, regulatory information changes, a reviewer identifies a problem, or clarity can be improved. Material corrections should be logged with the date and nature of the change. Routine copy edits that do not alter meaning do not require a correction notice.

Readers can report concerns through the corrections process. The goal is not to defend a draft. It is to make the published record more accurate and useful.

The operating cadence is monthly performance and link review, quarterly review of solution and comparison content, and an annual full-site audit. High-risk pages are reviewed sooner when a drug label, guideline, major study, product formula, safety issue, or ownership relationship changes. A last reviewed date should change only after a real source and content review.

For the site's broader purpose and scope, visit About HairLongevity.com.